This study was limited to four biomarkers and it is therefore conceivable that parallel evaluation of more hormonal and inflammatory GDM-associated markers, like sex hormone-binding globulin, C-reactive protein and/or sFRP5 [30,58,63,64], would strengthen our initial observation and thereby validate the use of a panel, including sFRP4, to predict the risk on GDM. This evidence concerns the gene SFRP5 and gestational diabetes.